Inteferon-based therapies for chronic Hepatitis C virus infection: an assessment of clinical outcomes
Husereau D, Bassett K, Koretz R
Record ID 32004000339
English, French
Authors' objectives:
This review explores the effectiveness of interferon (IFN)-based combination drugs by examining mortality and serious morbidity during the treatment of chronic hepatitis C virus (HCV) infection. We also consider the withdrawals due to adverse events, the quality of life and the virologic markers related to use of the following recommended treatments: - standard IFN plus ribavirin versus standard IFN therapy alone - standard IFN plus ribavirin versus pegylated IFN plus ribavirin.
Authors' recommendations:
- Information on quantity or quality of life related to IFN-based treatment is lacking. - Morbidity and mortality after therapy with ribavirin added to standard IFN could not be estimated from the randomized trial evidence. - Pegylated IFN combined with ribavirin can increase the need for urgent medical attention when compared with standard IFN plus ribavirin. - Pegylated IFN plus ribavirin therapy can reduce the risk of persistent viremia and liver enzyme elevation to the greatest degree, when it is compared with standard IFN plus ribavirin therapy or with standard IFN therapy alone.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antiviral Agents
- Drug Therapy, Combination
- Hepatitis C
- Interferons
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.